<DOC>
	<DOCNO>NCT01386359</DOCNO>
	<brief_summary>To describe Nulojix ( belatacept ) use determine often Post-Transplant Lymphoproliferative Disorder ( PTLD ) , Central Nervous System ( CNS ) PTLD Progressive Multifocal Leukoencephalopathy ( PML ) , rare serious complication transplant treatment , occur patient take Nulojix ( belatacept ) real-world setting .</brief_summary>
	<brief_title>Evaluating Nulojix ( Belatacept ) Long-Term Safety Transplant</brief_title>
	<detailed_description>Time Perspective : Prospective majority patient enrol time begin Nulojix ( belatacept ) treatment . Retrospective patient receive Nulojix ( belatacept ) prior enrollment ENLiST Registry</detailed_description>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Adult kidney transplant recipient ( age ≥18 year time transplant ) Kidneyonly transplant recipient Positive EBV serostatus ) EBV serostatus negative unknown include per investigator discretion Received first dose Nulojix ( Belatacept ) within ≤ 14 day renal transplant Received first dose Nulojix ( Belatacept ) part normal clinical care ( i.e . part clinical trial ) Received Nulojix ( belatacept ) non kidney transplant &lt; 18 year age time transplant Received first dose Nulojix ( belatacept ) assign study drug clinical trial protocol EBVserostatus negative unknown patient , except investigator decision Patient receive Belatacept de novo treatment Recipient concurrent extant nonkidney organ transplant Received first dose Nulojix ( belatacept ) &gt; 14 day date renal transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>